Glancy Prongay & Murray LLP Announces Investigation on Behalf of Corbus Pharmaceuticals Holdings, Inc. Investors

Business Wire 14-Mar-2019 5:47 PM

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Corbus Pharmaceuticals Holdings, Inc. investors ("Corbus" or the "Company") (NASDAQ: CRBP) concerning the Company and its officers' possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com.

On February 28, 2019, an article was published on Seeking Alpha alleging that Corbus "has ties to investors convicted of or alleged to have committed securities fraud" and that its drug candidate, lenabasum, is believed to have "failed its major trials in [systemic sclerosis] and [cystic fibrosis]." On this news, shares of Corbus fell $1.32 per share or nearly 16% to close at $6.94 per share on February 28, 2019, thereby injuring investors.

If you purchased Corbus securities, have information, or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 at 310-201-9150, Toll-Free at 888-773-9224, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number, and the number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190314005911/en/